Active Ingredient History

  • Now
Cidofovir is an antiviral nucleotide analogue with significant activity against cytomegalovirus (CMV) and other herpesviruses. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. Cidofovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.   NCATS

  • SMILES: NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
  • Mol. Mass: 279.187
  • ALogP: -1.66
  • ChEMBL Molecule:
More Chemistry
1-((3-hydroxy-2-phosphonylmethoxy)propyl)cytosine | 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-(s)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | 1-[(s)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | anhydrous cidofovir | cdv | cidofovir | cidofovir anhydrous | cidofovir dihydrate | cidofovir hydrate | cidofovir, (+-)-isomer | cidofovir monophosphate | cidofovir, (r)-isomer | cidofovir sodium | cidofovir, sodium salt | cidofovirum | cidovir | gs-0504 | gs 504 | gs-504 | hpmpc | (s)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine | (s)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | (s)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine | ({[(s)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid | [[(s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid | [(s)-2-(4-amino-2-oxo-2h-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid | (s)-(3-(4-amino-2-oxopyrimidin-1(2h)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid | (s)-hpmpc | sidofovir | vistide


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue